Literature DB >> 22419354

Single-incision apical and posterior mesh repair: 1-year prospective outcomes.

James C Lukban1, Jan-Paul W R Roovers, Douglas M Vandrie, Ty Erickson, Samuel Zylstra, Manish P Patel, Robert D Moore.   

Abstract

INTRODUCTION AND HYPOTHESIS: The objective of this study was to assess the safety and efficacy of the Elevate Apical and Posterior single-incision mesh system (SIMS) with IntePro Lite for pelvic organ prolapse repair.
METHODS: This prospective multicenter study included 139 women with ≥ stage II posterior vaginal prolapse and/or apical descent who underwent placement of type I polypropylene mesh through a single transvaginal incision with no external needle passes. Primary endpoint was the percent of patients with posterior and/or apical stage ≤ I ("cure") at follow-up. Secondary endpoints included, but were not limited to, rate of mesh extrusion and disease-specific quality of life outcomes.
RESULTS: At 12 months, objective posterior wall and apical cure rates were 92.5 and 89.2 %, respectively, with an extrusion rate of 6.5 %.
CONCLUSIONS: The SIMS appears to be effective and safe in treating patients with posterior vaginal and/or apical prolapse. The risks and benefits of transvaginal synthetic mesh insertion should be considered.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419354     DOI: 10.1007/s00192-012-1692-4

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  21 in total

1.  Procedures for pelvic organ prolapse in the United States, 1979-1997.

Authors:  Sarah Hamilton Boyles; Anne M Weber; Leslie Meyn
Journal:  Am J Obstet Gynecol       Date:  2003-01       Impact factor: 8.661

2.  The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction.

Authors:  R C Bump; A Mattiasson; K Bø; L P Brubaker; J O DeLancey; P Klarskov; B L Shull; A R Smith
Journal:  Am J Obstet Gynecol       Date:  1996-07       Impact factor: 8.661

3.  Anatomic aspects of vaginal eversion after hysterectomy.

Authors:  J O DeLancey
Journal:  Am J Obstet Gynecol       Date:  1992-06       Impact factor: 8.661

4.  Repair of vaginal vault prolapse and pelvic floor relaxation using polypropylene mesh.

Authors:  Matthew P Rutman; Donna Y Deng; Larissa V Rodriguez; Shlomo Raz
Journal:  Neurourol Urodyn       Date:  2005       Impact factor: 2.696

5.  Trocar-guided mesh compared with conventional vaginal repair in recurrent prolapse: a randomized controlled trial.

Authors:  Mariëlla I Withagen; Alfredo L Milani; Jan den Boon; Harry A Vervest; Mark E Vierhout
Journal:  Obstet Gynecol       Date:  2011-02       Impact factor: 7.661

6.  Perioperative morbidity using transvaginal mesh in pelvic organ prolapse repair.

Authors:  Daniel Altman; Christian Falconer
Journal:  Obstet Gynecol       Date:  2007-02       Impact factor: 7.661

7.  Sexual function in women before and after transvaginal mesh repair for pelvic organ prolapse.

Authors:  Loïc Sentilhes; Aurélien Berthier; Fabrice Sergent; Eric Verspyck; Philippe Descamps; Loïc Marpeau
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-06

Review 8.  Graft use in transvaginal pelvic organ prolapse repair: a systematic review.

Authors:  Vivian W Sung; Rebecca G Rogers; Joseph I Schaffer; Ethan M Balk; Katrin Uhlig; Joseph Lau; Husam Abed; Thomas L Wheeler; Michelle Y Morrill; Jeffrey L Clemons; David D Rahn; James C Lukban; Lior Lowenstein; Kimberly Kenton; Stephen B Young
Journal:  Obstet Gynecol       Date:  2008-11       Impact factor: 7.661

9.  Retrospective multicentre study of the new minimally invasive mesh repair devices for pelvic organ prolapse.

Authors:  M Abdel-Fattah; I Ramsay
Journal:  BJOG       Date:  2008-01       Impact factor: 6.531

10.  Does trocar-guided tension-free vaginal mesh (Prolift) repair provoke prolapse of the unaffected compartments?

Authors:  Mariëlla I J Withagen; Mark E Vierhout; Alfredo L Milani
Journal:  Int Urogynecol J       Date:  2009-11-10       Impact factor: 2.894

View more
  7 in total

1.  Evaluation of the single-incision Elevate system to treat pelvic organ prolapse: follow-up from 15 to 45 months.

Authors:  Kuan-Hui Huang; Li-Yi Huang; Li-Ching Chu; Fei-Chi Chuang; Ming-Ping Wu; Fu-Tsai Kung
Journal:  Int Urogynecol J       Date:  2015-04-30       Impact factor: 2.894

2.  Symptoms of voiding dysfunction and other coexisting pelvic floor dysfunctions: the impact of transvaginal, mesh-augmented sacrospinous ligament fixation.

Authors:  Maren Himmler; Martin Kohl; Aidana Rakhimbayeva; Magdalena Witczak; Alexander Yassouridis; Bernhard Liedl
Journal:  Int Urogynecol J       Date:  2021-01-27       Impact factor: 2.894

3.  Single-incision mesh repair versus traditional native tissue repair for pelvic organ prolapse: results of a cohort study.

Authors:  Tsung-Hsien Su; Hui-Hsuan Lau; Wen-Chu Huang; Ching-Hung Hsieh; Rhu-Chu Chang; Chin-Hui Su
Journal:  Int Urogynecol J       Date:  2014-01-28       Impact factor: 2.894

4.  Outcomes of trocar-guided Gynemesh PS™ versus single-incision trocarless Polyform™ transvaginal mesh procedures.

Authors:  Maryse Larouche; Lisa Merovitz; José A Correa; Jens-Erik Walter
Journal:  Int Urogynecol J       Date:  2014-07-24       Impact factor: 2.894

Review 5.  Where to for pelvic organ prolapse treatment after the FDA pronouncements? A systematic review of the recent literature.

Authors:  J M van Geelen; P L Dwyer
Journal:  Int Urogynecol J       Date:  2013-01-10       Impact factor: 2.894

6.  Effects of mesh-related complications in vaginal surgery on quality of life.

Authors:  Claudia R Kowalik; Mariëlle M E Lakeman; Alyde T de Kraker; Jan Paul W R Roovers
Journal:  Int Urogynecol J       Date:  2018-06-16       Impact factor: 2.894

7.  The impact of sacrospinous ligament fixation on pre-existing nocturia and co-existing pelvic floor dysfunction symptoms.

Authors:  Maren Himmler; Aidana Rakhimbayeva; Suzette E Sutherland; Jan-Paul Roovers; Alexander Yassouridis; Bernhard Liedl
Journal:  Int Urogynecol J       Date:  2020-08-11       Impact factor: 2.894

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.